A retrospective, nationwide cohort study of efficacy of vedolizumab in elderly versus younger inflammatory bowel disease patients
Latest Information Update: 03 Jul 2021
At a glance
- Drugs Vedolizumab (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Therapeutic Use
Most Recent Events
- 03 Jul 2021 New trial record
- 23 May 2021 Primary endpoint (steroid-free remission at week 52 after starting VDZ therapy) has not been met, according to Results presented at the Digestive Disease Week 2021.
- 23 May 2021 Results presented at the Digestive Disease Week 2021